

**(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)**

**(19) World Intellectual Property Organization  
International Bureau**



A standard linear barcode is located at the bottom of the page, spanning most of the width. It consists of vertical black bars of varying widths on a white background.

**(43) International Publication Date  
8 November 2007 (08.11.2007)**

PCT

(10) International Publication Number  
**WO 2007/125405 A3**

**(51) International Patent Classification:**

**C07D 239/84** (2006.01)      **C07D 403/12** (2006.01)  
**C07D 401/04** (2006.01)      **A61K 31/47** (2006.01)  
**C07D 401/12** (2006.01)      **A61P 3/10** (2006.01)

(74) **Agent:** FULLER, Grover, F., Jr.; c/o LAWRENCE, Jackie, Pfizer Inc. MS8260-1615, Eastern Point Road, Groton, CT 06340 (US).

**(21) International Application Number:**

PCT/IB2007/001123

**(22) International Filing Date:** 19 April 2007 (19.04.2007)

**(25) Filing Language:** English

**(26) Publication Language:** English

(30) Priority Data: 60/746,087 1 May 2006 (01.05.2006) US

(71) **Applicant (for all designated States except US): PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and  
(75) Inventors/Applicants (*for US only*): HUANG, Liming

(75) **Inventors/Applicants (for US only): HUANG, Liming** [US/US]; Agouron Pharmaceuticals Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **LIU, Song** [US/US]; Agouron Pharmaceuticals Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **LUNNEY, Elizabeth, Anna** [US/US]; Agouron Pharmaceuticals Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **PLANKEN, Simon, Paul** [GB/GB]; Agouron Pharmaceuticals Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (GB).

**(81) Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


**Published:**

— *with international search report*

**(88) Date of publication of the international search report:**  
17 January 2008

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**(54) Title:** SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS



**(57) Abstract:** The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: R<sup>1</sup>, R<sup>2</sup>, Z<sup>1</sup>, t, and ring A are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of JNK, such as diabetes, the method comprising administering to a mammal an effective amount of a compound of formula (I).

# INTERNATIONAL SEARCH REPORT

International application No

PCT/IB2007/001123

**A. CLASSIFICATION OF SUBJECT MATTER**

INV.	C07D239/84	C07D401/04	C07D401/12	C07D403/12	A61K31/47
	A61P3/10				

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, CHEM ABS Data, WPI Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 2007/000240 A (SANOFI AVENTIS DEUTSCHLAND GMB [DE]; PLETTENBURG OLIVER [DE]; HOFMEIST) 4 January 2007 (2007-01-04) pages 114-134 ----- X WO 01/81311 A (SCHERING AG [DE]; HUTH ANDREAS [DE]; SEIDELMANN DIETER [DE]; THIERAUCH) 1 November 2001 (2001-11-01) example 1.16 ----- X WO 2004/065378 A (WARNER LAMBERT CO [US]; BIWERSI CATHLIN MARIE [US]; McNAMARA DENNIS JO) 5 August 2004 (2004-08-05) pages 39-40 ----- -/-	1-15 1-15 1-15

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

8 October 2007

Date of mailing of the international search report

22/10/2007

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Lauro, Paola

## INTERNATIONAL SEARCH REPORT

International application No PCT/IB2007/001123
---

## C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/17995 A (MERCK & CO INC [US]; BILODEAU MARK T [US]; HUNGATE RANDALL W [US]; ROD) 15 March 2001 (2001-03-15) examples 9-14 -----	1-15
X	GIBSON K H ET AL: "Epidermal growth factor receptor tyrosine kinase: structure-activity relationships and antitumour activity of novel quinazolines" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 7, no. 21, 4 November 1997 (1997-11-04), pages 2723-2728, XP004136520 ISSN: 0960-894X compound 20 -----	1-15
X	BATHINI ET AL: "2-Aminoquinazoline inhibitors of cyclin-dependent kinases" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 15, no. 17, 1 September 2005 (2005-09-01), pages 3881-3885, XP005000600 ISSN: 0960-894X examples -----	1-15
X	KANUMA K ET AL: "Discovery of 4-(dimethylamino)quinazolines as potent and selective antagonists for the melanin-concentrating hormone receptor 1" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 15, no. 10, 16 May 2005 (2005-05-16), pages 2565-2569, XP004877725 ISSN: 0960-894X examples -----	1-15
X	SWANSON D M ET AL: "Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 48, no. 6, 12 November 2004 (2004-11-12), pages 1857-1872, XP002408466 ISSN: 0022-2623 example 35 -----	1-12
	-/-	

## INTERNATIONAL SEARCH REPORT

International application No PCT/IB2007/001123
---

## C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NEUMEYER; WEINHARDT: "3-(Dialkylaminoalkylamino)isoquinolines as Potential Antimalarial Drugs" J. MED. CHEM., vol. 13, no. 5, 1970, pages 999-1002, XP002453948 table I ----- US 3 535 321 A (DUNN GEORGE L) 20 October 1970 (1970-10-20) examples ----- K. SASSE: SYNTHESIS, May 1978 (1978-05), pages 379-382, XP002453949 examples ----- ZDROJEWSKI T ET AL: "A General Approach to 3-Aminoisoquinoline, Its N-Mono- and N,N-Disubstituted Derivatives" TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 51, no. 45, 6 November 1995 (1995-11-06), pages 12439-12444, XP004104710 ISSN: 0040-4020 Scheme 1 ----- WO 02/079197 A (VERTEX PHARMA [US]; BETHIEL RANDY [US]; COCHRAN JOHN [US]; MOON YOUNG-) 10 October 2002 (2002-10-10) the whole document ----- GRACZYK ET AL: "The neuroprotective action of JNK3 inhibitors based on the 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole scaffold" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 15, no. 21, 1 November 2005 (2005-11-01), pages 4666-4670, XP005088196 ISSN: 0960-894X the whole document -----	1-12 1-12 1-10 1-10 1-15 1-15

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No

PCT/IB2007/001123

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 2007000240	A	04-01-2007	AR	054518 A1	27-06-2007
WO 0181311	A	01-11-2001	AU BG BR CA CN CZ DE EE EP HK HR HU JP MX NO NZ PL SK YU ZA	5227201 A 107212 A 0110246 A 2406392 A1 1426396 A 20023545 A3 10021246 A1 200200609 A 1280776 A1 1056559 A1 20020933 A2 0300920 A2 2004512259 T PA02010559 A 20025102 A 521681 A 358457 A1 15222002 A3 71102 A 200209494 A	07-11-2001 30-05-2003 05-03-2003 01-11-2001 25-06-2003 12-02-2003 31-10-2001 15-04-2004 05-02-2003 23-02-2007 28-02-2005 28-07-2003 22-04-2004 10-03-2003 17-12-2002 31-03-2006 09-08-2004 03-06-2003 03-03-2006 14-07-2004
WO 2004065378	A	05-08-2004	BR CA EP JP MX	0406809 A 2512646 A1 1590341 A1 2006516561 T PA05007503 A	27-12-2005 05-08-2004 02-11-2005 06-07-2006 21-09-2005
WO 0117995	A	15-03-2001	AT AU AU BG BR CA CN CZ DE DE EE EP ES HU JP JP JP MX NO PL SK ZA	309241 T 779908 B2 7351700 A 106465 A 0013899 A 2384101 A1 1390215 A 20020861 A3 60023926 D1 60023926 T2 200200123 A 1218376 A1 2250186 T3 0202682 A2 3892296 B2 2003509342 T 2007045835 A PA02002559 A 20021166 A 355639 A1 4772002 A3 200201898 A	15-11-2005 17-02-2005 10-04-2001 29-12-2002 08-07-2003 15-03-2001 08-01-2003 12-06-2002 15-12-2005 20-07-2006 15-08-2003 03-07-2002 16-04-2006 28-02-2003 14-03-2007 11-03-2003 22-02-2007 30-07-2002 25-04-2002 04-05-2004 06-11-2002 07-03-2003
US 3535321	A	20-10-1970	NONE		
WO 02079197	A	10-10-2002	CA EP JP MX	2441733 A1 1373257 A1 2004529140 T PA03008888 A	10-10-2002 02-01-2004 24-09-2004 07-03-2005